Snima Kaniyampadi Sreenivasan, Pillai Prathesha, Cherian Aleena Mary, Nair Shantikumar V, Lakshmanan Vinoth-Kumar
Amrita Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham University, Kochi 682041, Kerala, India.
Curr Cancer Drug Targets. 2014;14(8):727-36. doi: 10.2174/1568009614666141020105502.
Metformin, a biguanide, is a commonly administered drug for the management of type 2 diabetes mellitus. The drug received tremendous recognition, when retrospective studies proved metformin-associated reduction in cancer risk. Metformin has potential anticancer effects and an ability to suppress tumor growth both in vitro and in vivo. Activation of LKB1/AMPK pathway and cancer stem cell destruction along with cell cycle arrest and apoptosis induction are the proposed mechanisms of anticancer potential of metformin. Nanotechnology approaches have also been adopted for metformin delivery to cancer cells. This review directs on the application of metformin for the therapy of various cancers and also the different pathways responsible for the metformin derived anticancer effect. It also focuses on the pharmacological applications of metformin and the nanotechnology approaches for metformin delivery.
二甲双胍是一种双胍类药物，是治疗2型糖尿病的常用药物。当回顾性研究证明二甲双胍可降低癌症风险时，该药物获得了广泛认可。二甲双胍具有潜在的抗癌作用，在体外和体内均有抑制肿瘤生长的能力。LKB1/AMPK通路的激活、癌症干细胞的破坏以及细胞周期停滞和凋亡诱导是二甲双胍抗癌潜力的推测机制。纳米技术方法也已被用于将二甲双胍递送至癌细胞。本综述聚焦于二甲双胍在各种癌症治疗中的应用以及导致二甲双胍抗癌作用的不同途径。它还关注二甲双胍的药理学应用以及二甲双胍递送的纳米技术方法。
